Annual Meeting

Papers and Posters

Accepted papers:

  • Medical-Surgical Hospitalizations by Veterans with Psychiatric and Substance Use Disorders
    David Moore, MD, PhD; Robert Rosenheck, MD,
  • Characteristics associated with long-acting naltrexone treatment persistence
    Grace Chang, MD, MPH; Abigail Schein, MD; Mitchell Crawford, DO
  • Unique and shared effects of alcohol, marijuana, and tobacco on electrophysiological signatures of reward and punishment processing, impulsivity, and affect in adolescent daily cigarette smokers
    Christopher Hammond, MD, PhD
  • Opioid Use Disorder and Homelessness in the Veterans Health Administration: The Challenge of Multi-morbidity
    Theddeus Iheanacho, MD
  • Smokeless Tobacco Use and Low Birth Weight Children Among Women in a Rural Setting of Chennai, India
    Delfin Lovelina Francis, MDS
  • Digital Natives in a Tele-Medical World: Evaluation of a Pilot Educational Elective in Tele-Addiction and Role of Tele- Medical Education in Addiction Fellowship
    Kathleen Broad, MD; Ismene Petrakis, MD; Ellen Edens, MD; Albert Arias, MD, MS
  • Highs and Lows of Cannabinoid-Dopamine Interaction: Effects of genetic and pharmacological modulation of COMT on the acute response to delta-9-tetrahydrocannabinol in humans
    Joao P. De Aquino, MD.; Mohini Ranganathan, MD; Rajiv Rhadhakrishnan, MD; Jose Cortes Briones, PhD; Brian Pittman, PhD; Deepak C. D’Souza, MD
  • Alcohol craving measured by the Penn Alcohol Craving Scale (PACS) predicts relapse risk after residential substance use disorder treatment
    Matthew Stohs, MD; Terry Schneekloth, MD; Jennifer Geske, MS; Joanna Biernacka, PhD; Victor Karpyak, MD, PhD
  • Neurocognitive Testing to Assess Efficacy of Substance Abuse Treatment in Residential Facilities
    Robert Lynn Horne, MD; Michael R. Adams, LCSW; Mark Calarco, MBA, DO
  • Why rimonabant (Acomplia)-induced dysphoria SHOULD have been expected
    Eliot Gardner, PhD
  • Efficacy of Buprenorphine (BPN) Depot Injections vs. Sublingual BPN for Opioid Use Disorder: A Phase 3 RCT
    Michelle Lofwall, MD; Edward V. Nunes, MD; Genie L. Bailey, MD; Sharon L. Walsh, PhD; Stacey C. Sigmon, PhD; Kyle M. Kampman, MD; Michael Frost, MD; Fredrik Tiberg, PhD; Margareta Linden, PhD; Sonia Oosman; Sonnie Kim, PharmD
  • The Impact of Treating Psychiatric Comorbidities On The Ability To Quit Smoking
    Maher Karam-Hage, MD

Accepted posters:

  • Medical Residents’ Attitudes Towards Patients with Substance Use Disorders
    Jonathan Avery, MD; Kristopher Kast, MD
  • Mortality in a Supportive Housing Program is Associated with Alcohol Use, Liver Disease, and HIV
    David Moore, MD, PhD; Robert Rosenheck, MD
  • Neurocognitive Testing to Determine ADHD in Residential Alcohol and Substance Abuse Patients
    Robert Lynn Horne, MD; Michael R. Adams, LCSW; Mark Calarco, MBA, DO
  • Engaging Adolescents: Animal-Assisted Therapy for Adolescents with Psychiatric and Substance Use Disorders
    Kate Trujillo, PhD, LCSW; Greg Kuo, MSW; Amanda Ingram, LCSW; Christian Thurstone, MD
  • Psychotherapy and three-year retention in buprenorphine treatment for opioid use disorder
    Ajay Manhapra, MD; Edeanya Agbese, MPH; Douglas Leslie, PhD; Robert Rosenheck, MD
  • Buprenorphine Treatment in Kentucky during 2009–2016 and the Effects of House Bill 1
    Anjali Dhanda, MD
  • Baclofen for AUD: a review of clinical evidence and practices
    Corina Freitas, MD, MSc, MBA, DC; Rdward Radden III, MD; Gerome Burke, MD, PhD
  • Transdisciplinary Training for those working with Co-Occurring Disorders
    Amelia Roeschlein, MA; Lawrence Malak, MD; Jennifer Lewis, Ph.D., LCSW
  • Assessment of Psychiatrists’ Practice Patterns for the Recognition and Management of Opioid Use Disorder
    Thomas Finnegan, PhD; Stacey Ullman, MHS; Paul Earley, MD
  • Use of Smartphone Apps as Complementary Treatment for Patients with Substance Use Disorders
    Jessica Allen; MD; LeTonia Adams, MD
  • Outpatient Transition to Extended-release Naltrexone in Patients With Opioid-use Disorder
    Maria Sullivan, MD, PhD; Paolo Mannelli, MD; Miao Yu, PhD; Narinder Nangia, PhD; Christine Graham, PhD; Irena Webster, MPH, MA; D. Andrew Tompkins, MD; Thomas Kosten, MD; Sarah Akerman, MD; Bernard Silverman, MD
  • Transition to Extended-release Naltrexone: Heroin Versus Prescription Opioid Users
    Paolo Mannelli, MD; D. Andrew Tompkins, MD, MHS; Sarah Akerman, MD; Miao Yu, PhD; Narinder Nangia, PhD; Christine Graham, PhD; Maria Sullivan, MD, PhD; Thomas Kosten, MD; Adam Bisaga, MD
  • Theoretical Domains Framework Survey Evaluation Identify Domains of Prescribers’ Behaviors with Benzodiazepiness< br />
    Melissa Christopher, Pharm.D.; Daina Wells, Pharm.D; Mark Bounthavong, Pharm.D., MPH; Marcos Lau, Pharm.D., MBA; Chad Kay, Pharm.D.; Sarah Popish, Pharm.D.; Julianne Himstreet, Pharm.D.; Michael Harvey, Pharm.D.
  • The Effectiveness of Gabapentin in Reducing Cravings and Withdrawal in Alcohol Dependence: A Meta-Analytic Review
    Saeed Ahmed, MD; Gregory Haggerty, MD; Ali Mahmood Khan, MD; Michael Esang, MD; Hema Madhuri Mekala, MD; Iqra Qamar, MD
  • Substance use disorders and their impact on the psychiatric & justice system
    Kristen Schmidt, MD; Kathryn Schak, MD
  • Extended-release Naltrexone Decreases Opioid Craving Across the 4-Week Dosing Interval
    Evgeny Krupitsky, MD, PhD; Adam Bisaga, MD; Narinder Nangia, PhD; Maria Sullivan, MD, PhD; Sarah Akerman, MD; Bernard Silverman, MD; Edward Nunes, MD/li>

  • Treatment retention and outcomes with the Adolescent Community Reinforcement Approach in emerging adults with opioid use
    Justine Welsh, MD; Valeria Tretyak, M.Res; M.S.; Lora L. Passetti, MS; Rodney R. Funk, BS; Jane Ellen Smith, PhD; Robert J. Meyers, Ph; Mark D. Godley, PhD
  • Buprenorphine Retention in Outpatient Mental Health: Comparing primary care and mental health outcomes in a large urban safety net hospital
    Brad Stankiewicz, MD; Cristina Montalvo, MD
  • Cardiovascular Disease as a Predictor of Psychological and Medical Problems in Veterans
    Alexandria Cantarero; Steven Batki, MD
  • Benzodiazepine Usage in an Outpatient Methadone Clinic Setting
    Bellelizabeth Foster, MD; Terry Stanton, MD; Snehal Bhatt, MD
  • The Effects of Repeated Delta-9-Tetrahydrocannabinol Administration to Adolescent Rhesus Monkeys on Working Memory
    David Mathai, MD; Christopher D. Verrico; Allan R. Sampson; David A. Lewis
  • Interaction Between Pre-Treatment Stimulant Use and Psychiatric Diagnoses on Treatment Outcomes in Adults with Co-Occurring Disorders
    Michael McDonnell, PhD; Oladunni Oluwoye, PhD; Katherine Hirchak, MS; Emily Leickly, BA; Jordan Skalisky, BA; Sterling McPherson, PhD; Debra Srebnik, PhD; John Roll, PhD; Richard Ries, MD
  • QTc Interaction of Lofexidine with Opioid Maintenance Medications: Methadone
    Charles Gorodetzky, MD, PhD.; James Longstreth, PhD; Aidan Hampson, PhD
  • QTc Interaction of Lofexidine with Opioid Maintenance Medications: Buprenorphine
    Charles Gorodetzky, MD, PhD; James Longstreth, PhD; Aidan Hampson, PhD
  • The Mannequin Challenge: Psychiatric Simulation using a Novel Case Involving Alcohol Withdrawal
    Ish Bhalla, MD; Kirsten Wilkins, MD; Jenna Butner, MD; Jeanette Tetrault, MD; David Moore, MD, PhD; Matthew Goldenberg, MD; Ambrose Wong, MD; Tiffany Moadel, MD; Brian Fuehrlein, MD, PhD
  • Kratom (Mitragynine) Use on the Rise: A Case Series from a VA Substance Treatment and Recovery Program
    Karen Hartwell, MD; Andrea Maxwell, MD
  • Rate of Screening for Substance Use Disorders in a Prenatal Clinic
    Katherine Callaghan, MD; Gillian Chase, MS3
  • Intrauterine Exposure to Methadone or Buprenorphine: Incidence and Severity of Neonatal Abstinence Syndrome
    Raghavendra Parige, MD, FAChAM(RACP) FASAM
  • Health Care Utilization and Costs Associated with Pharmacological vs. Non-Pharmacological Therapy for Opioid Dependence
    Ankit Shah, MS; Nipun Atreja, PhD; Kei Sing Tai, MS; Mugda Gore, PhD, B. Pharm; Margaret Duncan, MD
  • Examining the Effects of Varenicline on Cognition as a Function of Smoking Status in Patients with Schizophrenia and Controls
    Karolina Kozak, MSc; Tony George, M.D., FRCPC
  • Open Label Tolerability Study of Lofexidine HCl
    Marc Fishman, MD; Kristen Gullo, BS; Thomas Clinch; Danesh Alam, MD
  • Sex differences in the clinical psychiatric presentations of natural and synthetic cannabinoids users
    Anahita Bassirnia, MD; Daniel DeFrancisco, MD; Steven Carbonaro, MD; Sharon Spriggs, MS; Charles Perkel, MD; Igor Galynker, MD; Yasmin Hurd, PhD
  • OSCEs Identify SBIRT Training Needs for Medical Students
    Jennifer L. Smith, PhD; Edward Nunes, MD; Adam Bisaga, MD; Roberto Lewis-Fernandez, MD; Arthur Williams, MD; Aaron Krumheuer, BA; Frances Levin, MD
  • Substance Abuse and the Intentional Ingestion of Foreign Objects: Potential for Intervention
    Anna Lisa Derrien, MD; Daniel Safin, MD; Joel Wallack, MD
  • The Incorporation of SBIRT Training in Dental School Education
    Kelly Granger, D.D.S. Candidate 2020; Folarin Odusola, D.D.D; Frances Levin, MD; Jennifer L. Smith, PhD; Adam Bisaga, MD; Edward Nunes, MD
  • Attitudes and Knowledge About Fentanyl in Patients with Opioid Use Disorder
    Claudia Rodriguez, MD; Joji Suzuki, MD
  • Substance abuse in the elderly inpatient psychiatric population
    Ori-Michael Benhamou, MD, MMS; Elizabeth Leung, DO; Danielle Wolman
  • Stimulant use among a sample of college and medical students in the southern United States
    Juvraj Padda, MD; Jeeven Padda, MD; Nnenna Akoronu Okor, MS3; Vivek Anand, MD
  • Naloxone Overdose Kits: Assessment of Knowledge, Attitudes, and Barriers to Implementation Amongst Psychiatric Residents
    Jerry Joseph, MD; Merrill Herman, MD; Julia Arnsten, MD, MPH
  • The socio-structural implications of the ever changing landscape of bath salts
    Deepak Alapati, MBBS, MPH; Joseph Rasimas, MD, PhD, FAPM
  • Initial Appointments with Physicians: Missed Opportunities to Address Smoking
    James Walker, MD; David Friedrich, MD; Shalika Whig, MD; Karen Hartwell, MD
  • The Many Domains of Self-Efficacy and Their Individual Roles in the Treatment of Alcohol Use Disorder
    Marquette Rose, BS; Claire Wilcox, MD; Josh Clifford, BA; Michael Bogenschutz, MD; Rose Bigelow, MS
  • Association between binge drinking and the reason of drinking – A cross sectional study of college student of 35 colleges in Japan
    Kyoko Kawaida, MA; Hisashi Yoshimoto, MD; Go Saito, MD; Nobuaki Morita, MD; Sayuri Uchino, MD/li>

  • Electronic Cigarettes: Review of Safety and Use
    Sidarth Wakhlu, MD; Lindsay Chapman, DO; Adriane M. dela Cruz, MD, PhD
  • Opioid Death Trends (Accidental vs. Intentional) North Carolina vs. the United States of America
    Jessica Allen, MD; Vivek Anand, MD; Joseph Lee, PhD
  • New Opioids On The Horizon
    Allen Dsouza, MD; Senthil Vel Rajan Manoharan, MD; Erin Zerbo, MD
  • Predictors of Retention in Treatment for Opioid Use Disorder Following Administration of RBP-6000 vs. Placebo
    Celine Laffont, PhD; Eliford Ngaimisi, PhD; Mathangi Gopalakrishnan, PhD; Malcolm Young, PhD; Barbara Haight, PharmD; Sue Learned, MD, PharmD, PhD; Christian Heidbreder, PhD
  • Stimulant Misuse in adult ADHD with comorbid Substance Use Disorder (or Stimulant Use Disorder): Missing “ Due Diligence”: A Case Report and Literature Review
    Nuria Thusius, MD; Terry Schneekloth, MD; Shirshednu Sinha, MBBS
  • Drug-Related Mortality in Camden County and Gloucester County, N.J. Between 2013-2015
    Jessica Healey, BS; Karim Sedky, MD
  • Integrated Treatment for Persistent Depression and Alcohol Use Disorder: An Innovative Pilot Study
    Surbhi Khanna, MBBS; J. Kim Penberthy, PhD; Christopher Gioia, PhD
  • Factors affecting Long-term Retention on Opioid Agonist Maintenance Treatment in a Community Drug Treatment Clinic: A Retrospective Cohort Study from Indi
    Ravindra Rao, MD; Swati Kedia Gupta, PhD; Prashanth Ramshankar, MD; Alok Agrawal, MD; Atul Ambekar, MD; Anju Dhawan, MD
  • Determining Drinking Criteria for Transgender Veterans Entering Randomized Controlled Trials of Topiramate Treatment
    Edith Harris, BA; Ellen Herbst, MD; David L. Pennington, PhD; Gina Vitulano-Szefc, NP; Tessa Rife, PharmD, BCGP, and CACP; Steven L. Batki, MD; Fleurette Fong; Brooke Lasher; Alexander Kinzler; Jennifer Bielenberg; Lamisha Muquit; Melissa O’Donnell
  • Fatal Overdose Following Insufflation of an Unknown Substance
    Robert Rymowicz, DO; Pallavi Joshi, DO, MA
  • Buprenorphine/Naloxone Therapy in an Inner City Methadone Maintenance Treatment Program
    Jonathan Samuels, MD
  • Adderall Induced Delusional Parasitosis: A Case Report and Literature Review
    Martha J. Ignaszewski, MD; Deepika Sundararaj, MD; Erin Johnson, MD; Walter J Kilpatrick III, DO
  • ‘Gateway drugs’ and their relatedness to method of opioid administration
    Ruosi Liu, BS; Harry Haus, MD
  • Health care utilization and costs associated with opioid dependence treatments
    Ankit Shah, MS; Nipun Atreja, PhD; Xiaowu Sun, PhD; Kei Sing Tai, MS; Mugda Gore, PhD
  • What to Expect When They’re Withdrawing: support for integrated care models in pregnancy complicated by opioid use
    Marguerite Maguire, MD; Kimberley Parks, MD
  • Cannabis use and cocaine use are independent predictors of phencyclidine (PCP) use in DC Urban population with lower socioeconomic status
    Walid Aziz, MD: Partam Manalai, MD
  • Effects of Synthetic Cannabinoid in patients with Schizophrenia. A case report and literature Review
    Victor Nettey, MD, MPH
  • Prevalence of Behavioral and Emotional Problems in School going Adolescents in India
    Anshu Gupta
  • Characteristics of Sports Psychiatry Patients with Opioid Use Disorder
    Claire Twark, MD, MGH
  • Psilocybin-assisted treatment for alcohol use disorder: a clinical perspective
    Sean Amegadzie, Bachelor of Science, MD Candidate; Sarah Mennenga, PhD.; Samantha Podrebarac; Holly Duane, PhD; Stephen Ross, MD; Michael Bogenschutz, MD
  • Effects of Extended Cannabis Abstinence on Symptoms of Anxiety in Schizophrenia
    Aliya Lucatch, BSc; Rachel Rabin, PhD; Karolina Kozak, MSc; Tony George, MD, FRCPC
  • Amphetamines and Sex: Erectile Dysfunction and Reduced Sexual Satisfaction OR Positive Sexual Function?
    Nuria Thusius, MD; Christopher Sola, DO; J. Michael Bostwick, MD; Terry Schneekloth, MD
  • Opiate induced catatonia in a middle aged woman
    Fabrizzio Delgado, MD; Maria Velasco, MD; Joseph Yuen, MD
  • Association between alcohol-related injuries and aldehyde dehydrogenase 2 deficiency in college students: A cross-sectional study in Japan
    Hisashi Yoshimoto, MD; Ryohei Goto, PhD; Go Saito, MD; Kyoko Kawaida, RN; Yoshihiro Kataoka, PhD; Yousuke Takemura, PhD
  • Treatment of the Chemically Dependent Professional
    Christopher Rodgman, MD; Jay Piland, MD
  • Hand to God: Cannabis Psychosis and Withdrawal
    Nora Carson, MD; Patricia Ordorica, MD
  • Cost implications of illicit drug use in a psychiatric emergency program, a retrospective analysis
    Corina Freitas, MD, MSc, MBA; Jimmy Ibikunle, MBBS, MS
  • Effects of Extended-release Naltrexone Extend Beyond Exogenous Opioid Blockade: Clinical Trial Observations
    Edward Nunes, MD; Adam Bisaga, MD; Evgeny Krupitsky, MD; Narinder Nangia, PhD; Bernard Silverman, MD; Sarah Akerman, MD; Maria Sullivan, MD, PhD